IMPACT

Publication Reference

Chantrill LA, Nagrial AM, Watson C, Johns AL, Martyn-Smith M, Simpson S, Mead S, Jones MD, Samra JS, Gill AJ, Watson N, Chin VT, Humphris JL, Chou A, Brown B, Morey A, Pajic M, Grimmond SM, Chang DK, Thomas D, Sebastian L, Sjoquist K, Yip S, Pavlakis N, Asghari R, Harvey S, Grimison P, Simes J, Biankin AV. Precision medicine for advanced pancreas cancer: the Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) trial. Clinical Cancer Research 2015; 21(9): 2029-2037.

Conference Presentation Reference

1. Chantrill LA, Nagrial A, Johns A, McKay S, Gill AJ, Pavlakis N, Grimison PS, Asghari G, Waddell N, Chou A, Chin VT, Sebastian LT, Verghis J, Yip S, Sjoquist KM, Simes J, Biankin A. Clinical utilization of targetable molecular results in pancreatic cancer: longer-term outcomes from the Individualized Molecular Pancreatic Cancer Therapy (IMPACT) trial. Gastrointestinal Cancers Symposium; 19–21 Jan 2017; San Francisco.
2. Sebastian L, Verghis J, Simes J, Lee C, Sjoquist K, Biankin A, Nagrial A, Johns A, Gebski V, Grimison P, Pavlakis N, Asghari R, Miller D, Yip S, Thomas D, Chantrill L. Practical lessons from a pilot study of personalized treatment in pancreatic cancer: the IMPaCT study experience. An intergroup trial of the AGITG/NHMRC CTC/APGI/Kinghorn Cancer Centre/Sydney Catalyst. ACTA (Australian Clinical Trials Alliance) Symposium; 7–10 Oct 2015; Sydney.
3. Chantrill L, Sjoquist K, Lee C, Nagrial A, Johns A, Chin V, Chang D, Zalcberg J, Yip S, Biankin A, Simes J, Miller D, Sebastian L. Individualised molecular pancreatic cancer therapy. A randomised, open label, phase II trial assessing standard first line treatment with gemcitabine or personalised treatment based on tumour molecular signature in patients with recurrent or metastatic pancreatic cancer to evaluate feasibility and impact on progression free survival. Australasian Gastrointestinal Trials Group Annual Scientific Meeting; 20-22 Aug 2014; Brisbane.
4. Chantrill L, Johns A, Nagrial A, Chin V, Chou A, Pinese M, Mead S, Gebski V, Sjoquist K, Lee C, Yip S, Miller D, Sebastian L, Asghari R, Harvey S, Pavlakis N, Mukhedkar S, Grimison P, Miller D, Pearson J, Waddell N, Grimmond S, Simes J, Biankin A. The IMPaCT trial: Individualised Molecular Pancreatic Cancer Therapy. A pilot, randomised, open label phase II trial assessing first line treatment with gemcitabine or personalized treatment based on tumour molecular signature in patients with metastatic pancreatic cancer. American Association for Cancer Research-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference; 19–23 Oct 2013; Boston.
5. Nagrial A, Biankin A, Chantrill L, Johns A, Chin V, Gebski V, Sjoquist K, Lee C, Yip S, Miller D, Sebastian L, Pavlakis N, Mukhedkar S, Asghari R, Simes J. The IMPACT trial: Individualised Molecular Pancreatic Cancer Therapy. A randomised, open label, phase II trial assessing standard first line treatment with gemcitabine or personalised treatment based on tumour molecular signature in patients with recurrent or metastatic pancreatic cancer to evaluate feasibility and impact on progression free survival. Sydney Cancer Conference; 27–28 Sep 2012; Sydney.

Aim

A phase II trial assessing feasibility of personalised treatment based on tumour molecular signature in patients with recurrent or metastatic pancreatic cancer

Principal Investigator

Prof Andrew Biankin